Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial
Patients with multiple myeloma (MM) meeting frailty criteria have worse outcomes than those identified as non-frail. Here, we present a post hoc subgroup analysis of IMROZ, a global, phase III, open-label study investigating isatuximab (Isa) with bortezomib, lenalidomide, and dexamethasone (VRd) fol...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September, 2025
|
| In: |
Haematologica
Year: 2025, Jahrgang: 110, Heft: 9, Pages: 2139-2150 |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.2024.287200 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3324/haematol.2024.287200 Verlag, lizenzpflichtig, Volltext: https://haematologica.org/article/view/11994 
|
| Verfasserangaben: | Salomon Manier, Meletios-Athanasios Dimopoulos, Xavier P. Leleu, Philippe Moreau, Michele Cavo, Hartmut Goldschmidt, Robert Z. Orlowski, Muriel Tron, Christina Tekle, Marie-France Brégeault, Andrea T. Shafer, Meral Beksac and Thierry Facon |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1950977315 | ||
| 003 | DE-627 | ||
| 005 | 20260203104548.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260203s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2024.287200 |2 doi | |
| 035 | |a (DE-627)1950977315 | ||
| 035 | |a (DE-599)KXP1950977315 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Manier, Salomon |e VerfasserIn |0 (DE-588)1388852012 |0 (DE-627)195097829X |4 aut | |
| 245 | 1 | 0 | |a Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients |b a frailty subgroup analysis of the IMROZ trial |c Salomon Manier, Meletios-Athanasios Dimopoulos, Xavier P. Leleu, Philippe Moreau, Michele Cavo, Hartmut Goldschmidt, Robert Z. Orlowski, Muriel Tron, Christina Tekle, Marie-France Brégeault, Andrea T. Shafer, Meral Beksac and Thierry Facon |
| 264 | 1 | |c September, 2025 | |
| 300 | |b Diagramme | ||
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.02.2026 | ||
| 520 | |a Patients with multiple myeloma (MM) meeting frailty criteria have worse outcomes than those identified as non-frail. Here, we present a post hoc subgroup analysis of IMROZ, a global, phase III, open-label study investigating isatuximab (Isa) with bortezomib, lenalidomide, and dexamethasone (VRd) followed by Isa-Rd (N=265) versus VRd followed by Rd (N=181) in newly diagnosed transplant-ineligible MM (Ti NDMM) patients using the simplified International Myeloma Working Group (sIMWG) frailty score. Although patients aged >80 years were excluded, there was no exclusion for patients meeting frailty criteria. All patients received standard VRd/Rd dosing; Isa-VRd patients received intravenous Isa (cycle 1, 10 mg/kg once weekly; cycles 2-17, once every 2 weeks; subsequent cycles, once every 4 weeks). Patients with a frailty score of 0/1 were considered nonfrail; scores ≥2 were frail. Using this scoring, 26.7% of patients were frail (26.0% Isa-VRd; 27.6% VRd), and 72.0% non-frail (72.8% Isa-VRd; 70.7% VRd). After a median follow-up of 59.7 months, Isa-VRd significantly improved progression-free survival versus VRd in frail patients (hazard ratio [HR] =0.518; 95% confidence interval [CI]: 0.294-0.912; P=0.0227) and non-frail patients (HR=0.615; 95% CI: 0.419-0.903; P=0.0131). Significantly more frail patients receiving Isa-VRd than VRd achieved minimal residual disease negativity and complete response (odds ratio=3.459; 95% CI: 1.495-8.006; P=0.0030 at 10-5 by next-generation sequencing). Rates of treatment-emergent adverse events leading to definitive discontinuation were similar between both arms regardless of frailty status. This post hoc subgroup analysis of the IMROZ trial demonstrated that Isa-VRd is an effective option with a manageable safety profile for frail patients with Ti NDMM (clinicaltrials gov. Identifier: NCT03319667). | ||
| 700 | 1 | |a Dimopoulos, Meletios-Athanasios |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leleu, Xavier P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moreau, Philippe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cavo, Michele |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Orlowski, Robert Z. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tron, Muriel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tekle, Christina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brégeault, Marie-France |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shafer, Andrea T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beksac, Meral |e VerfasserIn |4 aut | |
| 700 | 1 | |a Facon, Thierry |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d Pavia : Ferrata Storti Foundation, 2014 |g 110(2025), 9 vom: Sept., Seite 2139-2150 |h Online-Ressource |w (DE-627)814204899 |w (DE-600)2805244-4 |w (DE-576)424051125 |x 1592-8721 |7 nnas |a Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients a frailty subgroup analysis of the IMROZ trial |
| 773 | 1 | 8 | |g volume:110 |g year:2025 |g number:9 |g month:09 |g pages:2139-2150 |g extent:12 |a Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients a frailty subgroup analysis of the IMROZ trial |
| 856 | 4 | 0 | |u https://doi.org/10.3324/haematol.2024.287200 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |7 1 |
| 856 | 4 | 0 | |u https://haematologica.org/article/view/11994 |x Verlag |z lizenzpflichtig |3 Volltext |7 1 |
| 951 | |a AR | ||
| 992 | |a 20260203 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 999 | |a KXP-PPN1950977315 |e 4874555179 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients","title_sort":"Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients","subtitle":"a frailty subgroup analysis of the IMROZ trial"}],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"September, 2025"}],"note":["Gesehen am 03.02.2026"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"12 S.","noteIll":"Diagramme"}],"name":{"displayForm":["Salomon Manier, Meletios-Athanasios Dimopoulos, Xavier P. Leleu, Philippe Moreau, Michele Cavo, Hartmut Goldschmidt, Robert Z. Orlowski, Muriel Tron, Christina Tekle, Marie-France Brégeault, Andrea T. Shafer, Meral Beksac and Thierry Facon"]},"relHost":[{"part":{"volume":"110","extent":"12","issue":"9","text":"110(2025), 9 vom: Sept., Seite 2139-2150","pages":"2139-2150","year":"2025"},"titleAlt":[{"title":"journal of the European Hematology Association"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients a frailty subgroup analysis of the IMROZ trialHaematologica","pubHistory":["99.2014 -"],"origin":[{"publisherPlace":"Pavia","dateIssuedDisp":"2014-","dateIssuedKey":"2014","publisher":"Ferrata Storti Foundation"}],"note":["Gesehen am 27.05.2022"],"title":[{"title":"Haematologica","title_sort":"Haematologica","subtitle":"journal of the European Hematology Association : journal of the Ferrata Storti Foundation"}],"id":{"eki":["814204899"],"issn":["1592-8721"],"zdb":["2805244-4"]},"recId":"814204899","physDesc":[{"extent":"Online-Ressource"}]}],"recId":"1950977315","id":{"eki":["1950977315"],"doi":["10.3324/haematol.2024.287200"]},"person":[{"role":"aut","given":"Salomon","family":"Manier","display":"Manier, Salomon"},{"family":"Dimopoulos","display":"Dimopoulos, Meletios-Athanasios","role":"aut","given":"Meletios-Athanasios"},{"display":"Leleu, Xavier P.","family":"Leleu","role":"aut","given":"Xavier P."},{"role":"aut","given":"Philippe","family":"Moreau","display":"Moreau, Philippe"},{"given":"Michele","role":"aut","display":"Cavo, Michele","family":"Cavo"},{"family":"Goldschmidt","display":"Goldschmidt, Hartmut","given":"Hartmut","role":"aut"},{"given":"Robert Z.","role":"aut","family":"Orlowski","display":"Orlowski, Robert Z."},{"display":"Tron, Muriel","family":"Tron","given":"Muriel","role":"aut"},{"display":"Tekle, Christina","family":"Tekle","role":"aut","given":"Christina"},{"family":"Brégeault","display":"Brégeault, Marie-France","given":"Marie-France","role":"aut"},{"display":"Shafer, Andrea T.","family":"Shafer","role":"aut","given":"Andrea T."},{"role":"aut","given":"Meral","display":"Beksac, Meral","family":"Beksac"},{"display":"Facon, Thierry","family":"Facon","role":"aut","given":"Thierry"}],"language":["eng"]} | ||
| SRT | |a MANIERSALOISATUXIMAB2025 | ||